Lyell Immunopharma (LYEL) Other Non-Current Liabilities (2020 - 2026)

Lyell Immunopharma's Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $527000.0 for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 83.22% year-over-year to $527000.0; the TTM figure through Mar 2026 stood at $527000.0 (down 83.22% YoY), while the FY2025 annual figure was $517000.0, down 84.11% from the prior year.
• Other Non-Current Liabilities came in at $527000.0 for Q1 2026 at Lyell Immunopharma, up from $517000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $4.5 million in Q1 2022 to a low of $517000.0 in Q4 2025.
• A 5-year average of $3.3 million and a median of $3.6 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities surged 382.22% in 2022 and sank 84.11% in 2025, its largest moves.
• Lyell Immunopharma's Other Non-Current Liabilities stood at $4.1 million in 2022, then slipped by 10.92% to $3.7 million in 2023, then slipped by 11.22% to $3.3 million in 2024, then tumbled by 84.11% to $517000.0 in 2025, then grew by 1.93% to $527000.0 in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $527000.0, $517000.0, and $2.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison